Previous Close | 10.99 |
Open | 11.19 |
Bid | 11.44 x 800 |
Ask | 11.45 x 800 |
Day's Range | 10.93 - 11.51 |
52 Week Range | 8.86 - 33.97 |
Volume | |
Avg. Volume | 2,983,443 |
Market Cap | 1.485B |
Beta (5Y Monthly) | 1.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.22 |
Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.83 |
VICTORIA, British Columbia, May 16, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and at the European Congress of Rheumatology, European Alliance of Associations for Rheumatology (EULAR) 2022. The 2022 ERA Congres
Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VICTORIA, British Columbia, May 10, 2022--AURINIA REPORTS FIRST QUARTER 2022 FINANCIAL AND OPERATIONAL RESULTS